Glooko - Today, we announced a strategic collaboration with Novo Nordisk that will benefit people with diabetes in Germany and other European markets through the development of connected insulin pen solutions. Through
![Novo Nordisk's soon-to-be-released insulin pens will connect to Glooko's diasend platform | MobiHealthNews Novo Nordisk's soon-to-be-released insulin pens will connect to Glooko's diasend platform | MobiHealthNews](https://www.mobihealthnews.com/sites/default/files/glooko_1.png)
Novo Nordisk's soon-to-be-released insulin pens will connect to Glooko's diasend platform | MobiHealthNews
![Novo Nordisk Pharma Ltd. and Health2Sync partner in Japan to expand digital diabetes management to healthcare providers and patients | MobiHealthNews Novo Nordisk Pharma Ltd. and Health2Sync partner in Japan to expand digital diabetes management to healthcare providers and patients | MobiHealthNews](https://www.mobihealthnews.com/sites/default/files/nnupdatedpic_Mobi_0.jpg)
Novo Nordisk Pharma Ltd. and Health2Sync partner in Japan to expand digital diabetes management to healthcare providers and patients | MobiHealthNews
![Contact a Novo Nordisk Hemophilia Community Liaison (HCL) | Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] Contact a Novo Nordisk Hemophilia Community Liaison (HCL) | Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei]](https://www.esperoct.com/content/dam/biopharm/esperoct/resources-for-you/connect-with-us/esperoct-connect-hero-desktop.png)